rs1044317 — ABCG1 ABCG1 3'UTR variant

ABCG1 — The HDL Maturation Transporter

ABCG1 (ATP-binding cassette transporter G1¹¹ ATP-binding cassette transporter G1
a membrane protein that pumps cholesterol out of cells into HDL particles in the bloodstream) is one of two master regulators of reverse cholesterol transport — the biological system that removes excess cholesterol from artery walls and returns it to the liver for disposal. While its partner ABCA1 initiates cholesterol loading onto nascent HDL particles, ABCG1 takes over, pumping additional cholesterol and phospholipids onto maturing HDL. Together they determine how efficiently your body can clear cholesterol from macrophage foam cells in arterial plaques.

The rs1044317 variant sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
the trailing sequence of the mRNA transcript after the protein-coding stop codon; it contains binding sites for regulatory microRNAs and elements that control mRNA stability and translation efficiency of ABCG1. Unlike missense variants that alter the protein's shape, this is a regulatory variant — it may affect how much ABCG1 protein your cells produce.

The Mechanism

The ABCG1 3'UTR harbors multiple microRNA binding sites³³ microRNA binding sites
microRNAs are short RNA molecules that bind to the 3'UTR and suppress gene expression by blocking translation or triggering mRNA degradation. Research has demonstrated that miR-128-2, for example, binds directly to the ABCG1 3'UTR with complete seed-sequence complementarity, reducing both ABCG1 mRNA and protein levels dose-dependently. Variants in the 3'UTR can create or disrupt such binding sites, altering how responsive ABCG1 expression is to these regulatory signals.

The A allele of rs1044317 (the GRCh38 reference, but the minor allele at ~43% globally) appears to tag a lower-expression ABCG1 haplotype. Reduced ABCG1 activity impairs the second step of reverse cholesterol transport — cholesterol efflux to mature HDL — leaving macrophages more prone to cholesterol accumulation and foam cell formation, an early driver of atherosclerotic plaques.

The Evidence

A case-control study of 541 coronary artery disease (CAD) patients and 649 healthy controls from a Chinese Han population⁴⁴ case-control study of 541 coronary artery disease (CAD) patients and 649 healthy controls from a Chinese Han population
Ma et al., Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2010 found that the A allele of rs1044317 was significantly more frequent in CAD patients than controls (OR 1.187, 95% CI 1.009–1.397, p=0.039). While this is a single-population study, the finding is biologically consistent with ABCG1's role in preventing foam cell formation.

A larger case-control study of 1,021 CAD patients and 1,013 controls from the same population⁵⁵ case-control study of 1,021 CAD patients and 1,013 controls from the same population
Xu et al., Atherosclerosis 2011 genotyped rs1044317 alongside other ABCG1 variants and confirmed that the ABCG1 locus on chromosome 21 is associated with CAD susceptibility in Han Chinese. The primary signal in that study came from a functional promoter variant (rs57137919, OR 0.73 protective), which may tag the same risk haplotype as rs1044317.

The mechanistic basis for ABCG1's cardiovascular role is well-established. A comprehensive review⁶⁶ comprehensive review
Frambach et al. 2020 Pharmacological Reviews concluded that ABCA1 and ABCG1 expression and function are rate-limiting steps for cholesterol efflux and that enhancing their activity represents a therapeutic strategy beyond LDL reduction. When ABCG1 is compromised, macrophages in artery walls accumulate cholesterol and form foam cells — the hallmark of early atherosclerotic plaques.

Practical Actions

Carriers of one or two A alleles can support cholesterol efflux through several targeted strategies. Omega-3 fatty acids (EPA/DHA) upregulate ABCG1 expression in macrophages through PPAR-gamma and LXR pathways. Niacin (vitamin B3) is one of the few pharmacological agents that raises ABCG1 expression while also increasing HDL-C. Regular fasting or time-restricted eating activates autophagy and ABCG1 upregulation in macrophages, promoting cholesterol efflux. Monitoring HDL function (cholesterol efflux capacity test) rather than just HDL-C quantity can provide more actionable information for A allele carriers.

Interactions

ABCG1 works in concert with ABCA1 (multiple common variants including rs2853579 and rs4783244) in a two-step relay. Reduced function of both transporters simultaneously produces a greater impairment of reverse cholesterol transport than either alone. The LIPC variant rs12593008 affects hepatic lipase, which remodels the HDL particles that ABCG1 loads — compound effects on HDL pathway function are possible across these loci. CETP variants (rs708272) affect cholesteryl ester transfer from HDL to LDL/VLDL, adding a third node of variation in the same pathway.